TY - JOUR
T1 - Association Between Whole Blood–Derived Mitochondrial DNA Copy Number, Low-Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk
AU - TOPMed mtDNA Working Group in NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
AU - Liu, Xue
AU - Sun, Xianbang
AU - Zhang, Yuankai
AU - Jiang, Wenqing
AU - Lai, Meng
AU - Wiggins, Kerri L.
AU - Raffield, Laura M.
AU - Bielak, Lawrence F.
AU - Zhao, Wei
AU - Pitsillides, Achilleas
AU - Haessler, Jeffrey
AU - Zheng, Yinan
AU - Blackwell, Thomas W.
AU - Yao, Jie
AU - Guo, Xiuqing
AU - Qian, Yong
AU - Thyagarajan, Bharat
AU - Pankratz, Nathan
AU - Rich, Stephen S.
AU - Taylor, Kent D.
AU - Peyser, Patricia A.
AU - Heckbert, Susan R.
AU - Seshadri, Sudha
AU - Boerwinkle, Eric
AU - Grove, Megan L.
AU - Larson, Nicholas B.
AU - Smith, Jennifer A.
AU - Vasan, Ramachandran S.
AU - Fitzpatrick, Annette L.
AU - Fornage, Myriam
AU - Ding, Jun
AU - Carson, April P.
AU - Abecasis, Goncalo
AU - Dupuis, Josée
AU - Reiner, Alexander
AU - Kooperberg, Charles
AU - Hou, Lifang
AU - Psaty, Bruce M.
AU - Wilson, James G.
AU - Levy, Daniel
AU - Rotter, Jerome I.
AU - Bis, Joshua C.
AU - Satizabal, Claudia L.
AU - Arking, Dan E.
AU - Liu, Chunyu
N1 - Publisher Copyright:
© 2023 The Authors.
PY - 2023/10/17
Y1 - 2023/10/17
N2 - BACKGROUND: The relationship between mitochondrial DNA copy number (mtDNA CN) and cardiovascular disease remains elusive. METHODS AND RESULTS: We performed cross-sectional and prospective association analyses of blood-derived mtDNA CN and cardiovascular disease outcomes in 27 316 participants in 8 cohorts of multiple racial and ethnic groups with whole-genome sequencing. We also performed Mendelian randomization to explore causal relationships of mtDNA CN with coronary heart disease (CHD) and cardiometabolic risk factors (obesity, diabetes, hypertension, and hyperlipidemia). P<0.01 was used for significance. We validated most of the previously reported associations between mtDNA CN and cardiovascular disease outcomes. For example, 1-SD unit lower level of mtDNA CN was associated with 1.08 (95% CI, 1.04–1.12; P<0.001) times the hazard for developing incident CHD, adjusting for covariates. Mendelian randomization analyses showed no causal effect from a lower level of mtDNA CN to a higher CHD risk (β=0.091; P=0.11) or in the reverse direction (β=−0.012; P=0.076). Additional bidirectional Mendelian randomization analyses revealed that low-density lipoprotein cholesterol had a causal effect on mtDNA CN (β=−0.084; P<0.001), but the reverse direction was not significant (P=0.059). No causal associations were observed between mtDNA CN and obesity, diabetes, and hypertension, in either direction. Multivariable Mendelian randomization analyses showed no causal effect of CHD on mtDNA CN, controlling for low-density lipoprotein cholesterol level (P=0.52), whereas there was a strong direct causal effect of higher low-density lipoprotein cholesterol on lower mtDNA CN, adjusting for CHD status (β=−0.092; P<0.001). CONCLUSIONS: Our findings indicate that high low-density lipoprotein cholesterol may underlie the complex relationships between mtDNA CN and vascular atherosclerosis.
AB - BACKGROUND: The relationship between mitochondrial DNA copy number (mtDNA CN) and cardiovascular disease remains elusive. METHODS AND RESULTS: We performed cross-sectional and prospective association analyses of blood-derived mtDNA CN and cardiovascular disease outcomes in 27 316 participants in 8 cohorts of multiple racial and ethnic groups with whole-genome sequencing. We also performed Mendelian randomization to explore causal relationships of mtDNA CN with coronary heart disease (CHD) and cardiometabolic risk factors (obesity, diabetes, hypertension, and hyperlipidemia). P<0.01 was used for significance. We validated most of the previously reported associations between mtDNA CN and cardiovascular disease outcomes. For example, 1-SD unit lower level of mtDNA CN was associated with 1.08 (95% CI, 1.04–1.12; P<0.001) times the hazard for developing incident CHD, adjusting for covariates. Mendelian randomization analyses showed no causal effect from a lower level of mtDNA CN to a higher CHD risk (β=0.091; P=0.11) or in the reverse direction (β=−0.012; P=0.076). Additional bidirectional Mendelian randomization analyses revealed that low-density lipoprotein cholesterol had a causal effect on mtDNA CN (β=−0.084; P<0.001), but the reverse direction was not significant (P=0.059). No causal associations were observed between mtDNA CN and obesity, diabetes, and hypertension, in either direction. Multivariable Mendelian randomization analyses showed no causal effect of CHD on mtDNA CN, controlling for low-density lipoprotein cholesterol level (P=0.52), whereas there was a strong direct causal effect of higher low-density lipoprotein cholesterol on lower mtDNA CN, adjusting for CHD status (β=−0.092; P<0.001). CONCLUSIONS: Our findings indicate that high low-density lipoprotein cholesterol may underlie the complex relationships between mtDNA CN and vascular atherosclerosis.
KW - Mendelian randomization
KW - cardiometabolic risk factors
KW - cardiovascular disease
KW - low-density lipoprotein cholesterol
KW - mitochondrial DNA copy number
KW - vascular atherosclerosis
UR - http://www.scopus.com/inward/record.url?scp=85175568680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175568680&partnerID=8YFLogxK
U2 - 10.1161/JAHA.122.029090
DO - 10.1161/JAHA.122.029090
M3 - Article
C2 - 37804200
AN - SCOPUS:85175568680
SN - 2047-9980
VL - 12
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 20
M1 - e029090
ER -